Citi analyst Liav Abraham upgraded Teva Pharmaceutical (TEVA) to Buy and raised her price target for the shares to $24 from $16. The drugmaker closed yesterday up 2c to $19.13.

The analyst “more constructive” on the Specialty Pharma group heading into 2018. More realistic expectations, along with pipeline catalysts set the stage for a potential inflection point for some of the stocks in 2018, Abraham tells investors in a research note on the sector. She believes Teva’s risk/reward profile that is skewed to the upside over the near to medium as management executes on the recently announced cost cuts.

Mylan (MYL) is Abraham’s top pick for 2018.
 

Print Friendly, PDF & Email

Related Posts